Skip to main content
Fig. 4 | Clinical Epigenetics

Fig. 4

From: Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer

Fig. 4

Circulating NPTX2 methylation status as prognostic biomarker in mPDAC patients. A Overall survival (OS) according to plasma RAS mutant allele fraction (MAF). B Progression-free survival (PFS) according to plasma RAS MAF. C OS according to CA19-9 level. D PFS according to CA19-9 level. E OS according to cfDNA concentration. F PFS according to cfDNA concentration. G OS according to NPTX2 methylation. H PFS according to NPTX2 methylation

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us